Literature DB >> 30885268

Correction to: Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial.

Angelos G Kolias1,2, Ellie Edlmann3,4, Eric P Thelin5,6, Diederik Bulters7, Patrick Holton7, Nigel Suttner8, Kevin Owusu-Agyemang8, Yahia Z Al-Tamimi9, Daniel Gatt9, Simon Thomson10, Ian A Anderson10, Oliver Richards10, Peter Whitfield11, Monica Gherle11, Karen Caldwell12, Carol Davis-Wilkie13, Silvia Tarantino12, Garry Barton14, Hani J Marcus15, Aswin Chari16, Paul Brennan17, Antonio Belli18, Simon Bond13,19, Carole Turner5,12, Lynne Whitehead20, Ian Wilkinson13, Peter J Hutchinson21,22.   

Abstract

After publication of the original article [1], the authors notified that that one of the BNTRC institutional collaborator names was misspelled.

Entities:  

Year:  2019        PMID： 30885268      PMCID： PMC6423751          DOI： 10.1186/s13063-019-3283-x

Source DB:  PubMed          Journal:  Trials        ISSN： 1745-6215            Impact factor:   2.279


Correction to: Trials (2018) 19:670 https://doi.org/10.1186/s13063-018-3050-4 After publication of the original article [1], the authors notified that that one of the BNTRC institutional collaborator names was misspelled. Both incorrect and correct spellings are presented below. Originally published name Ardalan Zolnouria Correct name spelling Ardalan Zolnourian
  1 in total

1.  Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial.

Authors:  Angelos G Kolias; Ellie Edlmann; Eric P Thelin; Diederik Bulters; Patrick Holton; Nigel Suttner; Kevin Owusu-Agyemang; Yahia Z Al-Tamimi; Daniel Gatt; Simon Thomson; Ian A Anderson; Oliver Richards; Peter Whitfield; Monica Gherle; Karen Caldwell; Carol Davis-Wilkie; Silvia Tarantino; Garry Barton; Hani J Marcus; Aswin Chari; Paul Brennan; Antonio Belli; Simon Bond; Carole Turner; Lynne Whitehead; Ian Wilkinson; Peter J Hutchinson
Journal:  Trials       Date:  2018-12-04       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.